In case you still didn't get Leo's shareholder letter.
My Fellow Shareholder,
I want to take a moment this morning to share with you an interesting article recently published by The Wall Street Journal. I encourage everyone to read John R. Emshwiller’s article, titled, “One Man’s Bid to Clear His Name Online: 4 Years, $3 Million and Some Dead Turtles.” The article struck a chord with me, as it lends some color to how certain characters leverage anonymity on the Internet to smear the good name of others only in an attempt to benefit themselves.
In his article, Mr. Emshwiller succinctly tells the story of real estate investor Bradley Cohen’s fight to expose the individuals behind an online assault on his business and character, make his name righteous again and bring the offenders to justice. Cohen must deal with fake news, relentless adversaries hiding behind the Frist Amendment, nefarious websites hosted in foreign countries and more.
Ultimately, Cohen’s perseverance paid off and he was successful on all counts, leading to a historic legal case and $38 million judgment in his favor.
I share this with all of you because it exemplifies that dark side of the Internet and the lengths that some bad actors will go to. It also proves that with persistent effort and the right resources that those individuals can be identified, no matter how cleverly they believe they have covered their tracks.
We assured you that the lawsuit by the Rosen Law Firm was frivolous. The court agreed. We didn’t stop there. You can believe me that our team is on top of bringing the culprits behind the attack on Cellceutix to justice.
We encourage current and future CTIX shareholders to rely only upon credible sources, including our news releases, research data and filings with the Securities and Exchange Commission. To that point, I am pleased to say that as of this morning we are still on target to provide an efficacy report this week from the second cohort in the open label Phase 2 trial of Brilacidin for ulcerative colitis. We also are looking forward in the coming weeks to releasing an interim analysis of data from the double-blind Phase 2 study of Brilacidin-OM for the prevention and treatment of oral mucositis.
These are truly exciting times at Cellceutix and I thank you for the ongoing support.
All the best,
Leo
My Fellow Shareholder,
I want to take a moment this morning to share with you an interesting article recently published by The Wall Street Journal. I encourage everyone to read John R. Emshwiller’s article, titled, “One Man’s Bid to Clear His Name Online: 4 Years, $3 Million and Some Dead Turtles.” The article struck a chord with me, as it lends some color to how certain characters leverage anonymity on the Internet to smear the good name of others only in an attempt to benefit themselves.
In his article, Mr. Emshwiller succinctly tells the story of real estate investor Bradley Cohen’s fight to expose the individuals behind an online assault on his business and character, make his name righteous again and bring the offenders to justice. Cohen must deal with fake news, relentless adversaries hiding behind the Frist Amendment, nefarious websites hosted in foreign countries and more.
Ultimately, Cohen’s perseverance paid off and he was successful on all counts, leading to a historic legal case and $38 million judgment in his favor.
I share this with all of you because it exemplifies that dark side of the Internet and the lengths that some bad actors will go to. It also proves that with persistent effort and the right resources that those individuals can be identified, no matter how cleverly they believe they have covered their tracks.
We assured you that the lawsuit by the Rosen Law Firm was frivolous. The court agreed. We didn’t stop there. You can believe me that our team is on top of bringing the culprits behind the attack on Cellceutix to justice.
We encourage current and future CTIX shareholders to rely only upon credible sources, including our news releases, research data and filings with the Securities and Exchange Commission. To that point, I am pleased to say that as of this morning we are still on target to provide an efficacy report this week from the second cohort in the open label Phase 2 trial of Brilacidin for ulcerative colitis. We also are looking forward in the coming weeks to releasing an interim analysis of data from the double-blind Phase 2 study of Brilacidin-OM for the prevention and treatment of oral mucositis.
These are truly exciting times at Cellceutix and I thank you for the ongoing support.
All the best,
Leo
1
